American Academy of Neurology 71st Annual Meeting (AAN)

May 4-10, 2019 | Philadelphia, PA

Abstracts featuring Neurofilament Light and Simoa Technology: 

1. Natalizumab Reduces Serum Concentrations of Neurofilament Light Chain in Secondary Progressive Multiple Sclerosis Patients From the Phase 3 ASCEND Study

Kapoor, Raju   Sellebjerg, Finn2 Hartung, Hans-Peter  Arnold, Douglas  Freedman, Mark S.  Jeffery, Douglas  Miller, Aaron  Edwards, Keith R.  Singh, Carol M.  Chang, Ih  Ren, Zhang  Sangurdekar, Dipen  Zhu, Bing  Mehta, Devangi  Ho, Pei-Ran  Campbell, Nolan  Edwards, Michael  Fisher, Elizabeth  Kieseier, Bernd C.  Rudick, Richard A.  Plavina, Tatiana 

1:00 PM - 3:00 PM, Monday, May 6

2. The Predictive Value of Neurofilament Light Chain Levels in Blood for Cognitive Impairment in Patients with Secondary Progressive Multiple Sclerosis

Kuhle, Jens  Kropshofer, Harald  Barro, Christian  Meinert, Rolf  Häring, Dieter  Leppert, David  Dahlke, Frank  Tomic, Davorka  Kappos, Ludwig

1:00 PM - 3:00 PM, Monday, May 6

3. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington’s disease

Rodrigues, Filipe B  Byrne, Lauren M  Johnson, Eileanoir  Wijeratne, Peter  de Vita, Enrico  Alexander, Daniel  Palermo, Giuseppe  Czech, Christian  Schobel, Scott  Scahill, Rachael  Heslegrave, Amanda  Zetterberg, Henrik  Wild, Edward

1:00 PM - 3:00 PM, Monday, May 6

4. Serum Neurofilament Light Chain as a Potential Biomarker for Spinal Muscular Atrophy Type I Disease Activity and Therapy Response

Deconinck, Nicolas  Peters, Thomas  Kieloch, Agnieszka  Valentin, Marie-Anne  Theil, Diethilde  Faller, Thomas  Jullien De Pommerol, Herve  Kakarieka, Algirdas

1:00 PM - 3:00 PM, Tuesday, May 7  

5. Serum Neurofilament Light (sNfL) for Disease Prognosis and Treatment Monitoring in Multiple Sclerosis Patients:Towards Implementation into Clinical Care

Calabresi, Peter A.  Kuhle, Jens  Arnold, Douglas L.  Kinkel, R. Philip  Kappos, Ludwig, Singh, Carol M.  Sangurdekar, Dipen  de Moor, Carl  Engle, Bob  Su, Ray  Deykin, Aaron  Fisher, Elizabeth  Sandrock, Alfred  Kieseier, Bernd C.  Rudick, Richard A.  Plavina, Tatiana

1:00 PM - 3:00 PM, Tuesday, May 7. Plans for introducing sNfL into clinical practice will also be presented.

6. Distinct Neurodegenerative and Neuroinflammatory Subtypes of HIV-associated Neurocognitive Disorders (HAND)

Smith, Bryan  Santamaria, Ulisses  Horne, Elizabeth  Saxena, Ankit  McCoy, Philip  Snow, Joseph  Nath, Avindra

3:30 PM - 5:30 PM, Tuesday, May 7 

7. Serum neurofilament light chain levels and cognitive performance in multiple sclerosis: a longitudinal retrospective 5-year study

Jakimovski, Dejan  Zivadinov, Robert  Ramanathan, Murali  Hagemeier, Jesper  Weinstock-Guttman, Bianca  Tomic, Davorka  Kropshofer, Harald  Barro, Christian  Leppert, David  Yaldizli, ÖZgüR  Kuhle, Jens  Benedict, Ralph 

1:00 PM - 3:00 PM, Wednesday, May 8 

8. Neurofilament-Light Chain Levels Are Predictive of On-going Disease Activity in Radiologically Isolated Syndrome

Thouvenot, Eric  Demattei, Christophe  Uygunoglu, Ugur  Pittion, Sophie  Castelnovo, Giovanni  Du Trieu de Terdonck, Luciel  Cohen, Mikael  Okuda, Darin  Kantarci, Orhun  Pelletier, Daniel  Marin, Philippe  Lehmann, Sylvain  Siva, Aksel  Lebrun Frenay, Christine 

1:00 PM - 3:00 PM, Wednesday, May 8

9. Serum Neurofilamant, GFAP and Tau in Patients with Aggressive Multiple Sclerosis Before and After Haematopoietic Stem Cell Transplant

Thebault, Simon  Tessier, Daniel  Bowman, Marjorie  Lee, Hyunwoo  Arnold, Douglas  Bar-Or, Amit  Tabard-Cossa, Vincent  Freedman, Mark 

1:00 PM - 3:00 PM, Wednesday, May 8

10. Monitoring of Subclinical Disease Activity by Serum Neurofilament Light Chain Levels in Multiple Sclerosis

Uher, Tomas  Schaedelin, Sabine  Benova, Barbora  Barro, Christian  Bergsland, Niels  Dwyer, Michael  Tyblova, Michaela  Kucerova, Karolina  Benkert, Pascal   Michalak, Zuzanna  Leppert, David  Naegelin, Yvonne  Krasensky, Jan  Seidl, Zdenek1  Vaneckova, Manuela  Kubala Havrdova, Eva6  Kappos, Ludwig  Zivadinov, Robert  Horakova, Dana  Kuhle, Jens  Kalincik, Tomas 

1:00 PM - 3:00 PM, Wednesday, May 8

11. The Correlation of Blood Neurofilament Light Chain with Brain Atrophy is Partly Independent from Inflammation

Sormani, *Maria Pia  Kappos, *Ludwig  A. Häring, Dieter  Kropshofer, Harald  Barro, Christian  Leppert, David  Tomic, *Davorka  Kuhle, *Jens 

1:00 PM - 3:00 PM, Wednesday, May 8  

12. The association between serum neurofilament light chain and OCT measures in multiple sclerosis

Hagemeier, Jesper  Tavazzi, Eleonora  Ramanathan, Murali  Jakimovski, Dejan  Bergsland, Niels  Tomic, Davorka  Kropshofer, Harald  Leppert, David  Michalak, Zuzanna  Dwyer, Michael  Benedict, Ralph  Weinstock-Guttman, Bianca  Kuhle, Jens  Zivadinov, Robert 

1:00 PM - 3:00 PM, Wednesday, May 8  

13. Clinical findings in amyotrophic lateral sclerosis type 4

Grunseich, Christopher  Wang, Isabel  Patankar, Aneesh  Schindler, Alice  Fischbeck, Kenneth  Cheung, Vivian 

3:30 PM - 5:30 PM, Thursday, May 9  

14. Neurofilament Light Chains as a Marker of Concurrent and Future Active Disease in Relapsing Multiple Sclerosis: An Analysis of Baseline Data From the Phase 3 Ozanimod Clinical Trials

Harris, Sarah  Comi, Giancarlo  Cree, Bruce A. C  Steinman, Lawrence  Sheffield, James K.   Silva, Diego  Southworth, Harry  Kappos, Ludwig 

Session Time:1:00 PM - 3:00 PM, Friday, May 10

15. Ocrelizumab treatment reduced levels of neurofilament light chain and numbers of B cells in the cerebrospinal fluid of patients with relapsing multiple sclerosis in the OBOE study

Cross, Anne  Bennett, Jeffrey  von Büdingen, Hans Christian  Carruthers, Robert  Edwards, Keith  Fallis, Robert  Fiore, Damian  Gelfand, Jeffrey  Giacomini, Paul  Greenberg, Benjamin  Hafler, David  Harp, Christopher  Assman, Beverly  Herman, Ann  Ionete, Carolina  Kaunzner, Ulrike  Lock, Christopher  Ma, Xiaoye  Musch, Bruno  Pardo, Gabriel  Piehl, Fredrik  Weber, Martin  Ziemssen, Tjalf  Bar-Or, Amit

1:00 PM - 3:00 PM, Friday, May 10

16. Gene therapy after onset of neuropathy provides therapeutic benefit in a model of CMT1X

Kleopa, Kleopas  Karaiskos, Christos  Richter, Jan  Tryfonos, Christina  Rossor, Alexander  Reilly, Mary  Sargiannidou, Irene  Christodoulou, Christina  Kagiava, Alexia 

1:00 PM - 3:00 PM, Friday, May 10

17. Neurofilament Light Chain (NfL) Levels in CSF, Serum, and Plasma of Healthy Donors Using the Quanterix NfL Advantage Kit™

Harp, Christopher T  Hendricks, Robert  Fischer, Sally K  Brumm, Jochen  Herman, Ann H 

11:30 AM - 6:30 PM, Sunday, May 5

18. SARM1 Loss of Function in Chronic and Acute CNS Axonopathies

Krauss, Raul  Hughes, Robert  Bosanac, Todd  Devraj, Rajesh  Engber, Thomas 

11:30 AM - 6:30 PM, Sunday, May 5

19. Neurofilament light test results vary substantially across different assay platforms and assay reagents

Deisenhammer, Florian  Podlesnic, Martina  Kuhle, Jens  Leppert, David  Michalak, Zuzanna  Deisenhammer, Julian  Schanda, Kathrin  Ehling, Rainer  Reindl, Markus 

11:30 AM - 6:30 PM, Sunday, May 5 

20. Establishment of Neurofilament Light Chain (NfL) SIMOA assay as well as a conversion factor to enable comparison to historical results using Bovine calibrators.

Hendricks, Robert  Davancaze, Teresa  Harp, Christopher  Herman, Ann  Baker, Dana  Brumm, Jochen  Von Budingen, H.  Townsend, Mike  Eggers, Erica  Fischer, Sally 

11:30 AM - 6:30 PM, Monday, May 6 

21. NfL Levels in CSF, Serum, and Plasma of RRMS and PPMS Patients in a Cross-sectional UCSF Cohort

Harp, Christopher T  Ma, Xiaoye  Hendricks, Robert  Fischer, Sally K  Eggers, Erica  Von Budingen, H.  Towsend, Michael  Herman, Ann H 

11:30 AM - 6:30 PM, Monday, May 6

21. From Mouse to Man – Translational Aspects of Serum Neurofilament Light Chain in Multiple Sclerosis

Zipp, Frauke  Steffen, Falk  Piepgras, Johannes  Fleischer, Vinzenz  Luessi, Felix  Groppa, Sergiu  Bittner, Stefan 

11:30 AM - 6:30 PM, Monday, May 6 

23. Exosomal and Plasma Protein Biomarkers of Neuronal Injury and Inflammation in Chronic Mild TBI: A Chronic Effects of Neurotrauma Consortium (CENC) Biomarker Discovery Project

Kenney, Kimbra  Shahim, Pashtun-Poh  Lai, Chen  Qu, Bao-Xi  Devoto, Christina  Walker, William  Diaz-Arrastia, Ramon  Gill, Jessica

11:30 AM - 6:30 PM, Monday, May 6

24. Exosome Proteins as Prognostic and Diagnostic Biomarkers for Mild Traumatic Brain Injury

Flamholz, Miranda  Beard, Kryshawna  Haber, Margalit  Yang, Zijian  Ko, Jina  Silverman, Erika  Meredith-Duliba, Tawny  Kulkarni, Nimay  Sandsmark, Danielle  Meaney, David  Issadore, David  Diaz-Arrastia, Ramon 

11:30 AM - 6:30 PM, Monday, May 6

26. Long-term Effect of Fingolimod in Reducing Blood Neurofilament Light Levels in Patients with Relapsing-remitting Multiple Sclerosis

Cohen, Jeffrey  Kappos, Ludwig  Tenenbaum, Nadia  Han, Jackie  Kropshofer, Harald  Tomic, Davorka  Kuhle, Jens 

11:30 AM - 6:30 PM, Tuesday, May 7

26. Effect of Ibudilast on Neurofilament-light Chain in Progressive MS: Analysis from a Phase II Trial

Fox, Robert  Karafa, Matthew  Konig, Victoria  Natarajan, Natarajan  Barro, Christian  Bermel, Robert  Coffey, Christopher  Goodman, Andrew  Klawiter, Eric  Matsuda, Kazuko  Naismith, Rober7  Kuhle, Jens 

11:30 AM - 6:30 PM, Tuesday, May 7

27. Serum Neurofilament Light Chain in a Phase 1/2 Trial of Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis

Baldassari, Laura  Planchon Pope, Sarah  Imrey, Peter  Bermel, Robert  Nakamura, Kunio  Fisher, Elizabeth  Feng, Jenny  Sakaie, Ken  Ontaneda, Daniel  Cohen, Jeffrey 

11:30 AM - 6:30 PM, Tuesday, May 7 

28. Effect of Alemtuzumab on Serum Neurofilament Light Chain Levels: Comparison to SC IFNB-1a and Assessment Over 7 Years (CARE-MS I)

Kuhle, Jens  Daizadeh, Nadia  Barro, Christian  Michalak, Zuzanna   Leppert, David  Godin, Jean  Shankara, Srinivas  Samad, Tarek A  Jacobs, Alan  Chung, Luke  Roesch, Nora  Kaiser, Carina  Kappos, Ludwig  Havari, Evis

11:30 AM - 6:30 PM, Tuesday, May 7  

29. Neurofilament Light Chain Levels In Pregnant Multiple Sclerosis Patients

Cuello, Juan Pablo  Martinez Ginés, Maria Luisa  Kuhle, Jens  Garcia Dominguez, Jose Manuel  Lozano Ros, Alberto  Romero Delgado, Fernando  Higueras, Yolanda  MeldañA Rivera, Ariana  Goicochea BriceñO, Haydee  Garcia Tizon, Santiago  De-Leon Ruiz, Juan  Alvarez Lafuente, Roberto  Domínguez-Mozo, Maria Inmaculada  Pérez-Pérez, Silvia  Medina Heras, Silvia  Fernández Velasco, Jose Ignacio  Tejeda-Velarde, Amalia  De Andres, Clara  Villar, Luisa Maria 

11:30 AM - 6:30 PM, Wednesday, May 8 

30. NFL pattern in progressive Multiple Sclerosis cohort under MD1003 treatment

Pignolet, Beatrice  Ammoscato, Francesca  Ciron, Jonathan  Bucciarelli, Florence  Scandella, Lise  Biotti, Damien  Lerebours, Fleur  Dorcet, Guillaume  Rabadeux, Céline  Freitas, Noellie  Bonneville, Fabrice  Gnanapavan, Sharmilee  Brassat, David 

11:30 AM - 6:30 PM, Wednesday, May 8 

31. Changes in the immune cell profile in fingolimod-treated patients with relapsing multiple sclerosis: primary analysis of the FLUENT study

Mao-Draayer, Yang  Cohen, Jeffrey  Bar-Or, Amit  Cree, Bruce A.C.  Han, May  Singer, Barry  Kolodny, Scott  Meng, Xiangyi  Schofield, Lesley  Ziehn, Marina 

11:30 AM - 6:30 PM, Wednesday, May 8 

32. Neurofilament Light Chain Protein Levels in HIV Positive Subjects with Neuropathy

Damian, Anne  Skolasky, Richard  Zetterberg, Henrik  Blennow, Kaj  Demsky, Cornelia  Gisslen, Magnus  McArthur, Justin  Sacktor, Ned 

11:30 AM - 6:30 PM, Wednesday, May 8

33. Plasma neurofilament light chain predicts disease progression in asymptomatic genetic frontotemporal dementia

Rojas -Martinez, Julio  Wang, Ping  Staffaroni, Adam  Cobigo, Yann  Wolf, Amy  Heuer, Hilary  Fong, Jamie  Taylor, Joanne  Jeromin, Andreas  Rosen, Howard  Boeve, Bradley  Boxer, Adam 

11:30 AM - 6:30 PM, Thursday, May 9

34. Serum Neurofilament Light Chain and Glial Fibrillary Acid Protein in Patients With Multiple Sclerosis

Ayrignac, Xavier  Maleska Maceski, Aleksandra  Carra-Dalliere, Clarisse  Charif, Mahmoud  Catteau, Cyndi  Ginestet, Nelly  Prin, Pauline  Corti, Lucas  Pinna, Frédéric  Lehmann, Sylvain  Labauge, Pierre 

11:30 AM - 6:30 PM, Thursday, May 9

35. The association between serum neurofilament light chain, atrophied lesion volume and brain atrophy with disability progression in multiple sclerosis

Tavazzi, Eleonora  Ramanathan, Murali  Barro, Christian  Hagemeier, Jesper  Jakimovski, Dejan  Bergsland, Niels  Tomic, Davorka  Kropshofer, Harald  Leppert, David  Michalak, Zuzanna  Dwyer, Michael  Benedict, Ralph  Weinstock-Guttman, Bianca  Kuhle, Jens  Zivadinov, Robert 

11:30 AM - 6:30 PM, Thursday, May 9

36. Serum GFAP Associates with Neurofilament Light and Disease Severity in Late Multiple Sclerosis

Airas, Laura  Hoegel, Heidi  Rissanen, Eero  Matilainen, Markus  Nylund, Marjo  Kuhle, Jens

11:30 AM - 6:30 PM, Thursday, May 9 

37.  Highly Sensitive Single Molecular Array Immunoassay Measurement of t-Tau, NF-L, GFAP, and UCH-L1 Biomarkers in Acute Concussion/Mild Traumatic Brain Injury (mTBI) Patient Serum and Saliva Samples
Chenna  A, Petropoulos CJ, and Winslow JW.

11:30 AM - 6:30 PM, Monday, May 6   

ACCESS ALL ABSTRACTS